Angiotensin II receptor blockers in heart failure

Pharmacotherapy

Volumn 23, Issue 2, 2003, Pages 173-182

  Patterson, Herbert ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ERYTHROMYCIN; FLUCONAZOLE; INOTROPIC AGENT; IRBESARTAN; ITRACONAZOLE; LOSARTAN; OLMESARTAN; PLACEBO; RIFAMPICIN; TELMISARTAN; VALSARTAN; VASODILATOR AGENT;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COUGHING; DIGOXIN BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FOLLOW UP; HEART FAILURE; HEART VENTRICLE REMODELING; HUMAN; HYPERURICEMIA; HYPOTENSION; INSULIN SENSITIVITY; META ANALYSIS; MONOTHERAPY; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; SIDE EFFECT; SUDDEN DEATH; TREATMENT OUTCOME; VERTIGO;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; RECEPTORS, ANGIOTENSIN;

EID: 0037322091     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.2.173.32095     Document Type: Short Survey

References (97)

1. American Heart Association. 2002 Heart and stroke statistical update. Dallas, TX: American Heart Association, 2001.
2. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
3. Francis GS, Goldsmith SR, Levine B, Olivari MT, Cohn JN. The neurohormonal axis in congestive heart failure. Ann Intern Med 1984;101:370-7.
4. Brunner-La Rocca H, Vaddadi G, Esler MD. Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism. J Am Coll Cardiol 1999;33:1163-73.
5. Stafford RS, Saglam D, Blumenthal D. National patterns of angiotensin-converting enzyme use in congestive heart failure. Arch Intern Med 1997;157:2460-4.
6. Philbin EF, Andreaou C, Rocco TA, Lynch LJ, Baker SL, Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol 1996;77:832-8.
7. Patterson JH, Adams KF. Pathophysiology of heart failure. Pharmacotherapy 1993;13(5 pt 2):73S-81.
8. Rouleau JL, De Champlain J, Klein M, et al. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol 1993;22:390-8.
9. Rouleau JL. The neurohormonal hypothesis and the treatment of heart failure. Can J Cardiol 1996;12(suppl F):3F-8.
10. 1-receptor blockers in hypertension and heart failure: clinical experience and future directions. Eur Heart J 1999;20:997-1008.
11. Dunn FG, Oigman W, Ventura HO, Messerli FH, Kobrin I, Frohlich ED. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol 1984;53:105-8.
12. Nakashima Y, Fouad FM, Tarazi RC. Regression of left ventricular hypertrophy from systemic hypertension by enalapril. Am J Cardiol 1984;53:1044-9.
13. Sutton MSJ, Pfeffer MA, Moye LA, et al, for the SAVE Investigators. Cardiovascular death and left ventricular remodeling two years after myocardial infarction; baseline predictors and impact of long-term use of captopril; information from the survival and ventricular enlargement (SAVE) trial. Circulation 1997;96:394-9.
14. Rutherford JD, Pfeffer MA, Moye LA, et al, for the SAVE Investigators. Effects of captopril on ischemic events after myocardial infarction: results of the survival and ventricular enlargement trial. Circulation 1994;90:1731-8.
15. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
16. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD pilot study investigators. Circulation 1999;100:1056-64.
17. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative north Scandinavian enalapril survival study. N Engl J Med 1987;316:1429-35.
18. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
19. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-8.
20. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-6.
21. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
22. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327:669-77.
23. Packer M. Assessment of treatment with lisinopril and survival (ATLAS). J Am Coll Cardiol 1998;32:1-7.
24. Luzier AB, Forrest A, Adelman M, Hawari FI, Schentag JJ, Izzo JL Jr. Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol 1998;82:465-9.
25. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
26. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.
27. Williams JL Jr, Bristow MR, Fowler MB, et al. Guidelines for the evaluation and management of heart failure: report of the American College of Cardiology-American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol 1995;26:1376-98.
28. Heart Failure Society of America. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction: pharmacological approaches. Pharmacotherapy 2000;20:495-522.
29. Jong P, Demers C, McKelvie RS, Liu PP. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol 2002;39:463-70.
30. de Gasparo M, Levens N. Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme? Pharmacol Toxicol 1998;82:257-71.
31. Urata H, Helaey B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990;66:883-90.
32. Urata H, Boehm KD, Philip A, et al. Cellular localization and regional distribution of angiotensin II-forming chymase in the heart. J Clin Invest 1993;91:1269-81.
33. Rousseau MF, Konstam MA, Benedict CR, et al. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol 1994;73:488-93.
34. Aldigier JC, Huang H, Dalmay F, et al. Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans. J Cardiovasc Pharmacol 1993;21:289-95.
35. Crozier I, Ikram H, Awan N, et al. Losartan in heart failure: hemodynamic effects and tolerability. Circulation 1995; 91:691-7.
36. Dickstein K, Chang P, Willenheimer R, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995;26:438-45.
37. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet 1997;349:747-52.
38. 1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. Am Heart J 2001;141:800-7.
39. Akishita M, Iwai M, Wu L, et al. Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice. Circulation 2000;102:1684-9.
40. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin type 2 receptor research in the cardiovascular system. Hypertension 1999;33:613-21.
41. 2 receptor. J Hum Hypertens 1998;12:311-18.
42. Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type-1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997;99:1926-35.
43. 2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol Cell Endocrinol 1996;122:59-67.
44. Morgan T. Effect of combining angiotensin receptor blockers and ACE inhibitors on cardiovascular disease. J Renin-Angiotensin-Aldosterone Sys 2001;2(suppl 1):S223-36.
45. Siragy HM, de Gasparo M, El-Kersh M, Carey RM. Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. Hypertension 2001;38:183-6.
46. Kim S, Zhan Y, Izumi Y, Iwao H. Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats. Circulation 2000;35:769-74.
47. Guazzi M, Palermo P, Pontone G, Susini F, Agostoni P. Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure. Am J Cardiol 1999;84:1038-43.
48. Hamroff G, Katz SD, Mancini D, et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999;99:990-2.
49. 1 and extracellular matrix in cardiac and vascular tissue of hypertensive rats. J Pharmacol Exp Ther 1995;273:509-15.
50. Obayashi M, Yano M, Kohno M, et al. Dose-dependent effect of ANG II-receptor antagonist on myocyte remodeling in rat cardiac hypertrophy. Am J Physiol 1997;273(4 pt 2):H1824-31.
51. Vacher E, Fornes P, Richer C, Bruneval P, Nisato D, Giudicelli JF. Early and late haemodynamic and morphological effects of angiotensin II subtype 1 receptor blockade during genetic hypertension development. J Hypertens 1995;14:675-82.
52. McCune SA, Carraway JW, Radin MJ, Holycross BJ. Comparison of irbesartan to captopril in heart failure prone male SHHF/MCCFAcp rats [abstr]. J Hypertens 1996; 14(suppl):S137.
53. Rockman HA, Wachorst SP, Mao L, Ross J Jr. ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. Am J Physiol 1994;226(6 pt 2):H2468-75.
54. Milavetz JJ, Raya TE, Morkin E, Goldman S. Survival after large myocardial infarction in rats: comparison of ACE inhibition with captopril versus direct angiotensin II blockade with losartan. J Am Coll Cardiol 1996;27:714-19.
55. Hayashi N, Fujimura Y, Yamamoto S, Kometani M, Nakao K. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 4th communication: improvement of heart failure of rats with myocardial infarction by valsartan. Arzniemettelforschung 1997;46:625-9.
56. Yoshiyama M, Kim S, Yamagishi H, et al. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J 1994;128:1-6.
57. Sleight P. Angiotensin II and trials of cardiovascular outcomes. Am J Cardiol 2002;89(suppl 2A):11A-16.
58. Lewis J, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
59. Pitt B, Poole-Wilson PA, Segal R, et al, for the ELITE II Investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the losartan heart failure survival study ELITE II. Lancet 2000;355:1582-7.
60. Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002;40:1414-21.
61. Swedberg K, Pfeffer M, Granger C, et al, for the CHARM- Programme Investigators. Candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Fail 1999;5:276-82.
62. Dahlöf B, Devereux RB, Kjeldsen SE, et al, for the LIFE Study Group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
63. Lindholm LH, Ibsen H, Dahlöf B, et al, for the LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.
64. Pfeffer MA, McMurray J, Leizorovicz A, et al, for the VALIANT Investigators. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000;140:727-34.
65. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752-60.
66. Mann J, Julius S, for the VALUE Trial Group. The valsartan antihypertensive long-term use evaluation (VALUE) trial of cardiovascular events in hypertension: rationale and design. Blood Pressure 1998;7:176-83.
67. Julius S. Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Cardiology 1999;91(suppl 1):8-13.
68. Kjeldsen SE, Julius S, Brunner H, et al, for the VALUE Trial Group. Characteristics of 15,314 hypertensive patients at high coronary risk: the VALUE trial. Blood Pressure 2001;10:1-11.
69. Riegger GAJ, Bouzo H, Petr P, et al. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation 1999;100:2224-30.
70. Havranek WP, Thomas I, Smith WB, et al. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. J Am Coll Cardiol 1999;33:1174-81.
71. Pylypchuk GB. ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother 1998;32:1060-6.
72. Merck & Co. Inc. Cozaar (losartan potassium) product information. Whitehouse Station, NJ; 2001.
73. Frye CB, Pettigrew TJ. Angioedema and photosensitive rash induced by valsartan. Pharmacotherapy 1998;18:866-8.
74. Messerli FH, Weber MA, Brunner HR. Angiotensin II receptor inhibition: a new therapeutic principle. Arch Intern Med 1996;156:1957-65.
75. Mimran A, Ribstein J. Angiotensin receptor blockers: pharmacology and clinical significance. J Am Soc Nephrol 1999;10:S273-7.
76. Hebert LA, Falkenhain ME, Nahman NS Jr, Cosio FG, O'Dorisio TM. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol 1999;19:1-6.
77. Burnier M, Rutschmann B, Nussberger J, et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993;22:339-47.
78. Burnier M, Hagmann M, Nussberger J, et al. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995;25:602-9.
79. Burnier M, Brunner HR. Renal effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibition in healthy subjects. Exp Nephrol 1996;4(suppl 1):41-6.
80. Nakagawa H, Daihara M, Tamakawa H, Nozue T, Kawahara K. Effects of quinapril and losartan on insulin sensitivity in genetic hypertensive rats with different metabolic abnormalities. J Cardiovasc Pharmacol 1999;34:28-33.
81. Moan A, Hoieggen A, Nordby G, Eide IK, Kjeldsen SE. Effects of losartan on insulin sensitivity in severe hypertension: connections through sympathetic nervous system activity? J Hum Hypertens 1995;9(suppl 5):545-50.
82. Fogari R, Zoppi A, Corradi L, Lazzari P, Mugellini A, Lusardi P. Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of nondiabetic hypertensive patients. Br J Clin Pharmacol 1998;46:467-71.
83. Brenner BM, Cooper ME, de Zeeuw D, et al, for the RENAAL Study Investigators. The losartan renal protection study: rationale, study design and baseline characteristics of RENAAL (reduction of endpoints in NIDDM with the angiotensin II antagonist losartan). J Renin-Angiotensin-Aldosterone Sys 2000;1:328-35.
84. Brenner BM, Cooper ME, de Zeeuw D, et al, for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
85. Lewis J, Hunsicker LG, Clarke WR, et al, for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
86. Parving H-H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
87. Viberti G, Wheeldon NM, for the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106;672-8.
88. Muirhead N, Feagan BF, Mahon J, et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial. Curr Ther Res 1999;60:650-60.
89. Csajka C, Buclin T, Brunner HR, Biollaz J. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Clin Pharmacokinet 1997;32:1-29.
90. Markham A, Goa KL. Valsartan: a review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997;54:299-311.
91. Gillis JC, Markham A. Irbesartan: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997;54:885-902.
92. McClellan KJ, Goa KL. Candesartan cilexetil: a review of its use in essential hypertension. Drugs 1998;56:847-69.
93. McClellan KJ, Markham A. Telmisartan. Drugs 1998;56: 1039-44.
94. Bottorff MB, Tenero DM. Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations. Pharmacotherapy 1999;19(4 pt 2):73S-8.
95. Kaukonen KM, Olkkola KT, Neuvonen PJ. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol 1998;53:445-9.
96. Williamson KM, Patterson JH, McQueen RH, Adams KF Jr, Pieper JA. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 1998;63:316-23.
97. Bourrie M, Meunier V, Berger Y, Fabre G. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes. Drug Metab Dispos 1999;27:288-96.